DAL BEN, Diego
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.291
EU - Europa 6.741
AS - Asia 4.409
SA - Sud America 568
AF - Africa 197
Continente sconosciuto - Info sul continente non disponibili 28
OC - Oceania 9
Totale 24.243
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.940
CN - Cina 1.759
PL - Polonia 1.721
RU - Federazione Russa 1.326
SG - Singapore 1.301
IT - Italia 1.138
DE - Germania 595
BR - Brasile 473
GB - Regno Unito 434
FR - Francia 370
HK - Hong Kong 365
VN - Vietnam 353
UA - Ucraina 336
CA - Canada 298
SE - Svezia 258
FI - Finlandia 221
KR - Corea 153
ZA - Sudafrica 139
TR - Turchia 132
IE - Irlanda 92
IN - India 87
JP - Giappone 67
NL - Olanda 52
BE - Belgio 40
AR - Argentina 37
MX - Messico 36
BD - Bangladesh 32
ES - Italia 28
EU - Europa 27
AT - Austria 22
IQ - Iraq 18
TW - Taiwan 16
CZ - Repubblica Ceca 15
PK - Pakistan 15
EC - Ecuador 14
AE - Emirati Arabi Uniti 13
LT - Lituania 13
CO - Colombia 12
IR - Iran 12
KE - Kenya 12
RO - Romania 12
RS - Serbia 12
PY - Paraguay 10
TN - Tunisia 10
CH - Svizzera 9
EG - Egitto 9
JO - Giordania 9
SA - Arabia Saudita 9
UZ - Uzbekistan 9
VE - Venezuela 9
DK - Danimarca 8
ID - Indonesia 8
AU - Australia 7
LB - Libano 7
PE - Perù 7
DZ - Algeria 6
IL - Israele 6
AM - Armenia 5
AZ - Azerbaigian 5
HU - Ungheria 5
MA - Marocco 5
PH - Filippine 5
AL - Albania 4
BG - Bulgaria 4
CI - Costa d'Avorio 4
HR - Croazia 4
MY - Malesia 4
NP - Nepal 4
BY - Bielorussia 3
CL - Cile 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
GR - Grecia 3
LV - Lettonia 3
NO - Norvegia 3
TT - Trinidad e Tobago 3
GE - Georgia 2
HN - Honduras 2
JM - Giamaica 2
KH - Cambogia 2
KW - Kuwait 2
NG - Nigeria 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
OM - Oman 2
PT - Portogallo 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
CM - Camerun 1
DM - Dominica 1
EE - Estonia 1
GD - Grenada 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LU - Lussemburgo 1
Totale 24.230
Salva come PNG Salva come JPEG
Città #
Warsaw 1.494
Fairfield 1.295
Ashburn 1.078
Woodbridge 971
Jacksonville 793
Singapore 670
Houston 625
Chandler 567
San Jose 546
Seattle 539
Wilmington 514
Ann Arbor 483
Cambridge 449
Dallas 366
Boardman 353
Hong Kong 344
Beijing 299
Camerino 259
Nanjing 246
Kraków 213
Toronto 202
Los Angeles 189
The Dalles 153
Seoul 127
Johannesburg 124
New York 120
Helsinki 118
San Mateo 117
Tongling 116
Dearborn 111
Lawrence 111
Princeton 111
Columbus 107
Ho Chi Minh City 107
London 106
Istanbul 104
Lauterbourg 100
Council Bluffs 97
Moscow 91
Dublin 90
Ogden 89
Düsseldorf 81
Chicago 74
San Diego 73
Buffalo 72
Nanchang 71
Shanghai 71
Guangzhou 69
Milan 63
Hanoi 60
São Paulo 59
Lachine 57
Tokyo 53
Munich 51
Frankfurt am Main 50
Dong Ket 49
Santa Clara 48
Tianjin 48
Kunming 46
Edinburgh 44
Shenyang 43
Brussels 39
Jiaxing 38
Orem 38
Hebei 36
Centro 35
Rome 34
Atlanta 26
Changsha 26
Manchester 26
Denver 25
Hangzhou 25
Philadelphia 25
Trieste 25
San Francisco 24
Jinan 23
Wuhan 23
Falls Church 22
Phoenix 22
Poplar 22
Redwood City 22
Amsterdam 21
Hefei 20
Ningbo 20
Norwalk 20
Redondo Beach 20
Scafati 20
Boston 19
Chennai 19
Montreal 18
Nuremberg 18
Stockholm 18
Bologna 16
Brooklyn 16
Jinhua 16
Rio de Janeiro 16
Turku 16
Verona 16
Zhengzhou 16
Salt Lake City 15
Totale 16.672
Salva come PNG Salva come JPEG
Nome #
1,2,4-Triazolo[1,5-a]quinoxaline derivatives and their simplified analogues as adenosine A3 receptor antagonists. Synthesis, structure–affinity relationships and molecular modeling studies 635
A2AR agonists/A3R antagonists: design, synthesis, and biological evaluation of new ligands with dual activity 437
The Length and Flexibility of the 2-Substituent of 9-Ethyladenine Derivatives Modulate Affinity and Selectivity for the Human A2A Adenosine Receptor 402
Overview on Radiolabel-Free in Vitro Assays for GPCRs 397
Pharmacological characterization of the GPR17 receptor dual profile 379
The 1,2,4-Triazolo[4,3-a]pyrazin-3-one as a Versatile Scaffold for the Design of Potent Adenosine Human Receptor Antagonists. Structural Investigations to Target the A2A Receptor Subtype 376
GPR17 receptor modulators and their therapeutic implications: review of recent patents 373
The G Protein-Coupled Receptor GPR17: Overview and Update 366
2′,3′-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 358
Stabilization of the cyclodecadiene derivative isofuranodiene by silver (I) coordination. Mechanistic and biological aspects 358
2’,3’-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 348
Emerging Roles of Purinergic Signaling in Diabetes 347
Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications 304
A Novel Class of Dopamine D4 Receptor Ligands Bearing an Imidazoline Nucleus 294
Adenine based acyclic-nucleotides as novel P2X3 receptor ligands 290
Synthesis and antitumor evaluation of bis aza-anthracene-9,10-diones and bis aza-anthrapyrazole-6-ones 288
8-(2-Furyl)adenine derivatives as A2A adenosine receptor ligands 286
Neuroprotective potential of adenosine A1 receptor partial agonists in experimental models of cerebral ischemia 280
P2X7 Receptor as a Therapeutic Target 273
Neuropeptide S Receptor: recent updates on non-peptide antagonist discovery 271
Simulation and Comparative Analysis of Different Binding Modes of Non-nucleoside Agonists at the A2A Adenosine Receptor 265
Medicinal Chemistry of P2X Receptors: Agonists and Orthosteric Antagonists 263
Investigation on 2′,3′-O-Substituted ATP Derivatives and Analogs as Novel P2X3 Receptor Antagonists 263
Approaches for designing and discovering purinergic drugs for gastrointestinal diseases 247
Ex-vivo absorption study of lysine R-lipoate salt, a new pharmaceutical form of R-ALA 244
Antiproliferative Evaluation of Isofuranodiene on Breast and Prostate Cancer Cell Lines 240
New substituted 9-propyladenine derivatives as A2Aadenosine receptor antagonists 233
Antioxidant-conjugated 1,2,4-Triazolo[4,3-a]pyrazin-3-one Derivatives: Highly Potent and Selective Human A2A Adenosine Receptor Antagonists Possessing Protective Efficacy in Neuropathic Pain 233
Design, synthesis, and biological evaluation of new mitonafide derivatives as potential antitumor drugs 231
Innovative functional cAMP assay for studying G protein-coupled receptors: application to the pharmacological characterization of GPR17 230
8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A(2A) and A(2B) receptors ligands 230
Purinergic P2X receptors: Structural models and analysis of ligand-target interaction 227
“Third Joint Italian-German Purine Club Meeting - Purinergic Receptors: New Frontiers for Novel Therapies” 226
Identification of a specific residue that confers BzATP sensitivity to P2X2 receptors 224
New sensible method to quantize the intestinal absorption of receptor ligands 222
Non-Nucleoside Agonists of the Adenosine Receptors: An Overview 221
A(2A) Adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists 219
The P2X7 Receptor in Infection and Inflammation 219
Molecular modeling studies on the human neuropeptide S receptor and its antagonists. 218
Evidence for the existence of a specific G protein-coupled receptor activated by guanosine 216
Exploring the 7-oxo-thiazolo[5,4-d]pyrimidine core for the design of new human adenosine A3 receptor antagonists. Synthesis, molecular modeling studies and pharmacological evaluation 216
Molecular modeling study on potent and selective adenosine A3 receptor agonists. 214
Antiviral properties of deazaadenine nucleoside derivatives 214
Adenosine A(2A) receptor antagonists: new 8-substituted 9-ethyladenines as tools for in vivo rat models of Parkinson's disease 210
Design, synthesis and evaluation in an LPS rodent model of neuroinflammation of a novel (18)F-labelled PET tracer targeting P2X7 210
Novel human adenosine receptor antagonists based on the 7-amino-thiazolo[5,4-d]pyrimidine scaffold. Structural investigations at the 2-, 5- and 7-positions to enhance affinity and tune selectivity 207
Interaction model for anthracycline activity against DNA topoisomerase II 206
Comparison and optimization of transient transfection methods at human astrocytoma cell line 1321N1 204
Adenosine receptor modeling: what does the A2A crystal structure tell us? 203
Different efficacy of adenosine and NECA derivatives at the human A3 adenosine receptor: Insight into the receptor activation switch 203
Fragment optimization for GPCRs by molecular dynamics free energy calculations: Probing druggable subpockets of the A2A adenosine receptor binding site 202
Identification of alpha(1)-adrenoceptor subtypes involved in contraction of young CD rat epididymal vas deferens 201
Imidazo[1,2-a]pyrazin-8-amine core for the design of new adenosine receptor antagonists: Structural exploration to target the A3 and A2A subtypes 201
Novel 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives as potent human adenosine A1 and A2A receptor antagonists. Evaluation of their protective effect against β-amyloid-induced neurotoxicity in SH-SY5Y cells 199
Purinergic Ligands as Potential Therapeutic Tools for the Treatment of Inflammation-Related Intestinal Diseases 198
Simulation and comparative analysis of binding modes of nucleoside and non-nucleoside agonists at the A2B adenosine receptor 197
New 2,6,9-trisubstituted adenines as adenosine receptor antagonists: a preliminary SAR profile 196
The aminopyridine-3,5-dicarbonitrile core for the design of new non-nucleoside-like agonists of the human adenosine A2B receptor 196
The importance of alkynyl chain presence for the activity of adenine nucleosides/nucleotides on purinergic receptors 195
Pharmacological postconditioning of the rabbit heart with non-selective, A1, A2A and A3 adenosine receptor agonists 195
Innovative functional cAMP assay: application to the pharmacological characterization of GPR17 193
Amide bond direction modulates G-quadruplex recognition and telomerase inhibition by 2,6 and 2,7 bis-substituted anthracenedione derivatives 192
A3 Adenosine Receptor Antagonists with Nucleoside Structures and Their Anticancer Activity 191
GPCRs as therapeutic targets: a view on adenosine receptors structure and functions, and molecular modeling support 189
Evaluation of adenine as scaffold for the development of novel P2X3 receptor antagonists 189
Modifications on the amino-3,5-dicyanopyridine core to obtain multifaceted adenosine receptor ligands with antineuropathic activity 188
Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors 185
Amino-3,5-Dicyanopyridines Targeting the Adenosine Receptors Ranging from Pan Ligands to Combined A1/A2B Partial Agonists 184
A2A Adenosine Receptor Antagonists: Are Triazolotriazine and Purine Scaffolds Interchangeable? 181
Human adenosine A3 receptor as selective target of new 2-aralkynyl-N6-methyl-MECA derivatives 180
Adenosine Receptors as Neuroinflammation Modulators: Role of A1 Agonists and A2A Antagonists 176
Synthesis, structure-affinity relationships and molecular modeling studies of novel pyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists 175
Synthesis and stability studies of 2 ',3 ',5 '-tri-O-acetyl-2-amino(-N-6-cyclopentyl)-1-deazaadenosines 174
Pyrazolo[1,5-c]quinazoline derivatives and their simplified analogues as adenosine receptor antagonists. Synthesis, structure-affinity relationships and molecular modeling studies 174
I protocolli operativi nella violenza di genere 174
TESTING D2-LIKE RECEPTOR AFFINITY AND SELECTIVITY WITH NOVEL IMIDAZOLINE DERIVATIVES 173
DNA Topoisomerase II Structures and Anthracycline Activity: Insights into Ternary Complex Formation 170
Functional cAMP assay optimization at CHO cells expressing A2A adenosine receptors and stably transfected with firefly luciferase biosensor 168
Rational design of new competitive inhibitors of human CK2 activity 166
Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease 163
Purinergic P2X receptors: Structural models and analysis of receptor-ligand interaction 161
Development of novel pyridazinone-based adenosine receptor ligands 160
Highlights on the development of A(2A) adenosine receptor agonists and antagonists 157
N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A(3) adenosine receptor 152
Synthesis and biological activity of trisubstituted adenines as A(2A) adenosine receptor antagonists 151
New potent and selective A1 adenosine receptor antagonists as potential tools for the treatment of gastrointestinal diseases 149
Substituted adenine derivatives as novel P2X3 receptor ligands 148
7th Joint Italian-German Purine Club Meeting - “Advances in basic and translational purinergic research” - 20-22 luglio 2017 148
New purine derivatives as P2X3 receptor antagonists 145
Adenine derivatives as inhibitors of the casein kinase CK1delta enzyme 144
GTP-Eu binding assay optimization for the adenosine A3 receptor ligands screening 144
The Anti-Inflammatory and Pain-Relieving Effects of AR170, an Adenosine A3 Receptor Agonist, in a Rat Model of Colitis 144
Letters in Drug Design & Discovery 142
A2A adenosine receptor ligands: effects on alcohol intake in alcohol-preferring rats 141
Adenosine A2A Receptor Antagonists: Chemistry, SARs, and Therapeutic Potential 140
Existence of snoRNA, microRNA, piRNA characteristics in a novel non-coding RNA: x-ncRNA and its biological implication in Homo sapiens 140
Synthesis and biological evaluation of 2-alkynyl-N6-methyl-5'-N-methylcarboxamidoadenosine derivatives as potent and highly selective agonists for the human adenosine A(3) receptor 139
“Dual Anta-Inhibitors” of the A2A Adenosine Receptor and Casein Kinase CK1delta: Synthesis, Biological Evaluation, and Molecular Modeling Studies 135
null 134
New 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives. Evaluation of different moieties on the 6-aryl ring to obtain potent and selective human A2A adenosine receptor antagonists 131
Totale 22.290
Salva come PNG Salva come JPEG
Categoria #
all - tutte 93.739
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 93.739
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021847 0 0 0 0 0 0 0 0 0 222 369 256
2021/20221.488 184 371 33 41 67 66 86 124 111 145 92 168
2022/20231.440 164 103 56 230 137 188 9 74 245 70 109 55
2023/20241.247 161 64 80 49 57 114 65 92 138 44 45 338
2024/20254.107 180 74 330 195 135 258 476 1.025 340 283 277 534
2025/20265.496 367 349 702 813 641 453 1.012 451 400 308 0 0
Totale 24.669